{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T13:18:44Z","timestamp":1787750324688,"version":"build-2784847793"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>A diagnosis of cancer creates a stressful situation owing to the uncertainties related to the thought of possible suffering from complications associated with treatment toxicities, the fear of not responding to the prescribed treatment, or death. The prevalence of mental health disorders is relatively higher in cancer patients vis-\u00e0-vis the general population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We performed a retrospective cohort study to evaluate the impact of mental health disorders on outcomes of relapsed and\/or refractory diffuse large B-cell lymphoma (DLBCL) treated with chimeric antigen receptor T-cell (CAR T-cell) therapy using data from the TriNetX research network.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 1587 patients met the inclusion criteria (858 with a mental health diagnosis and 729 without). After propensity score matching for age and gender, 1320 patients were included in the analysis (660 in each group). The 1-year OS was higher in patients without a mental health disorder (76.0% versus 69.4%,\n                      <jats:italic toggle=\"yes\">P\u2009<\/jats:italic>\n                      =\u20090.004). Patients with mental health disorders had a higher incidence of cytokine release syndrome (all grades) compared with those without (35.5% versus 27.6%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001) and immune effector cell-associated neurotoxicity syndrome (all grades) (16.8% versus 10.1%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>These findings emphasize the importance of thorough psychiatric evaluation and management in patients receiving CAR T-cell therapy. Patients with mental health disorders may need significant assistance with coordinating medical services to better adhere to required care management. Future studies are needed to help determine whether preventive and real-time mental health interventions can favorably impact outcomes of these patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/hemoncstem.hemoncstem-d-26-00018","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T08:01:30Z","timestamp":1782201690000},"page":"37-43","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Impact of mental health on outcomes of patients with relapsed and\/or refractory diffuse large B-cell lymphoma treated with chimeric antigen receptor T-cell therapy"],"prefix":"10.4103","volume":"19","author":[{"given":"Mohamed A.","family":"Kharfan-Dabaja","sequence":"first","affiliation":[{"name":"Division of Hematology-Oncology and Blood and Marrow Transplantation and Cellular Therapy Program, Mayo Clinic, Jacksonville, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios","family":"Tsalatsanis","sequence":"additional","affiliation":[{"name":"Research Methodology and Biostatistics Core, Office of Research, Morsani College of Medicine, University of South Florida, Tampa, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet S.","family":"Uyanik","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology and Blood and Marrow Transplantation and Cellular Therapy Program, Mayo Clinic, Jacksonville, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taimur","family":"Sher","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology and Blood and Marrow Transplantation and Cellular Therapy Program, Mayo Clinic, Jacksonville, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Qin","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology and Blood and Marrow Transplantation and Cellular Therapy Program, Mayo Clinic, Jacksonville, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Aljurf","sequence":"additional","affiliation":[{"name":"Department of Hematology, Stem Cell Transplantation and Cellular Therapy, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio C.","family":"Chavez","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology and Blood and Marrow Transplantation and Cellular Therapy Program, Mayo Clinic, Jacksonville, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambuj","family":"Kumar","sequence":"additional","affiliation":[{"name":"Research Methodology and Biostatistics Core, Office of Research, Morsani College of Medicine, University of South Florida, Tampa, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"key":"R1-20260623","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"R2-20260623","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"R3-20260623","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): A multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"R4-20260623","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"key":"R5-20260623","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","article-title":"Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): Interim analysis of a phase 3 trial","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"key":"R6-20260623","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/ajh.26538","article-title":"Mental health among patients with non-Hodgkin lymphoma: A Danish nationwide study of psychotropic drug use in 8750 patients and 43 750 matched comparators","volume":"97","author":"Ovlisen","year":"2022","journal-title":"Am J Hematol"},{"key":"R7-20260623","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1080\/0284186X.2021.1992008","article-title":"Prevalence of mental disorders in patients with cancer compared to matched controls\u2014secondary analysis of two nationally representative surveys","volume":"61","author":"Vehling","year":"2022","journal-title":"Acta Oncol"},{"key":"R8-20260623","doi-asserted-by":"crossref","first-page":"e530","DOI":"10.1016\/S2352-3026(23)00094-7","article-title":"Mental health disorders and survival among older patients with diffuse large B-cell lymphoma in the USA: A population-based study","volume":"10","author":"Kuczmarski","year":"2023","journal-title":"Lancet Haematol"},{"key":"R9-20260623","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.hpb.2020.08.002","article-title":"Association of preexisting mental illness with all-cause and cancer-specific mortality among Medicare beneficiaries with pancreatic cancer","volume":"23","author":"Paredes","year":"2021","journal-title":"HPB (Oxford)"},{"key":"R10-20260623","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.1200\/JCO.2017.73.4947","article-title":"Impact of preexisting mental illness on all-cause and breast cancer-specific mortality in elderly patients with breast cancer","volume":"35","author":"Iglay","year":"2017","journal-title":"J Clin Oncol"},{"key":"R11-20260623","doi-asserted-by":"crossref","first-page":"4508","DOI":"10.1182\/blood-2024-198053","article-title":"Impact of preexisting mental health disorders on CAR T-cell therapy outcomes in patients with large B-cell lymphoma","volume":"144","author":"Gouni","year":"2024","journal-title":"Blood"},{"key":"R12-20260623","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1182\/blood.2024024526","article-title":"Efficacy of CAR T-cell therapy is not impaired by previous bispecific antibody treatment in large B-cell lymphoma","volume":"144","author":"Crochet","year":"2024","journal-title":"Blood"},{"key":"R13-20260623","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3390\/curroncol33020085","article-title":"Real-world outcomes of axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma in Canada","volume":"33","author":"Lemieux","year":"2026","journal-title":"Curr Oncol"},{"key":"R14-20260623","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"R15-20260623","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/cncr.34557","article-title":"Perception of prognosis, quality of life, and distress in patients receiving chimeric antigen receptor T-cell therapy","volume":"129","author":"Dhawale","year":"2023","journal-title":"Cancer"}],"container-title":["Hematology\/Oncology and Stem Cell Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/hemoncstem.HEMONCSTEM-D-26-00018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T12:24:40Z","timestamp":1787747080000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/hemoncstem.HEMONCSTEM-D-26-00018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/hemoncstem.hemoncstem-d-26-00018","relation":{},"ISSN":["1658-3876","2589-0646"],"issn-type":[{"value":"1658-3876","type":"print"},{"value":"2589-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"2026-04-28","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-17","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}